Qiagen (NYSE:QGEN) Stock Dropped to “Hold” by DZ Bank

Qiagen (NYSE:QGEN) was downgraded by equities researchers at DZ Bank from a “strong-buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks reports.

Several other research firms have also recently weighed in on QGEN. Citigroup restated a “neutral” rating and set a $45.00 price target (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Weiss Ratings raised Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $52.00 price objective (down from $55.00) on shares of Qiagen in a report on Thursday. Morgan Stanley reiterated an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. Four investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $44.43.

Qiagen Stock Performance

Shares of Qiagen stock opened at $50.42 on Thursday. The stock has a market cap of $10.39 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 4.99 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The firm’s 50-day moving average is $44.44 and its 200 day moving average is $40.64.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The firm had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. During the same quarter in the previous year, the firm earned $0.60 earnings per share. The company’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts anticipate that Qiagen will post 2.44 EPS for the current fiscal year.

Institutional Trading of Qiagen

Several hedge funds have recently made changes to their positions in QGEN. Engineers Gate Manager LP lifted its position in Qiagen by 107.7% in the second quarter. Engineers Gate Manager LP now owns 74,567 shares of the company’s stock worth $2,916,000 after buying an additional 38,658 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in Qiagen during the first quarter valued at $2,518,000. Baader Bank Aktiengesellschaft bought a new position in Qiagen during the first quarter valued at $1,368,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Qiagen in the second quarter valued at $2,836,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Qiagen in the second quarter valued at $1,423,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.